Prescription Pricing for the People Act of 2025
Sponsor
Full profile: /officials/G000386
Source: Congress.gov · FEC
Cosponsors (13)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
- Christopher A. Coons (D-DE)Original· 2025-02-11
- James Lankford (R-OK)Original· 2025-02-11
- Maria Cantwell (D-WA)Original· 2025-02-11
- Mazie K. Hirono (D-HI)Original· 2025-02-11
- Peter Welch (D-VT)Original· 2025-02-11
- Richard Blumenthal (D-CT)Original· 2025-02-11
- Roger Marshall (R-KS)Original· 2025-02-11
- Shelley Moore Capito (R-WV)Original· 2025-02-11
- Thom Tillis (R-NC)Original· 2025-02-11
- Tommy Tuberville (R-AL)Original· 2025-02-11
- John Boozman (R-AR)· 2025-04-02
- Marsha Blackburn (R-TN)· 2025-04-07
- Raphael G. Warnock (D-GA)· 2025-07-09
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
2025-04-10
Source: Congress.gov
Committee Activity
Currently in
- Senate Committee on the JudiciaryReported By · 2025-04-10
Previously
- Judiciary CommitteeReported By · 2025-04-10
- Judiciary CommitteeMarkup By · 2025-04-03
- Senate Committee on the JudiciaryMarkup By · 2025-04-03
- Judiciary CommitteeReferred To · 2025-02-11
- Senate Committee on the JudiciaryReferred To · 2025-02-11
Plain-English Summary
Prescription Pricing for the People Act of 20 25 This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs. The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs. The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations. Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.
Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.
Subjects
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- SRES939A resolution expressing the sense of the Senate that it values the active participation of the Republic of Kosovo as the state partner of the Iowa National Guard over the past 15 years.Introduced · 2026-09-30
- S5611SRBIJA ActReferred to Committee · 2026-09-30
- SRES927A resolution designating the week beginning October 18, 2026, as "National Character Counts Week".Introduced · 2026-09-29
- S5583Small Agri-Biodiesel Producer Credit Extension ActReferred to Committee · 2026-09-29